Figure 7

BENC-511 induces MM cell death in vivo and delays tumor growth in myeloma xenograft models. Human multiple myeloma cells (RPMI-8226 and OPM2) were injected subcutaneously into nude mice with a density of 30 million cells/site. When tumors were palpable, mice (n = 10/group) were orally given BENC-511 (50 mg/Kg body weight) in PBS containing 10% Tween 80 and 10% DMSO daily for continuous 20 days. Tumor volumes (A) were monitored every other day. *, p < 0.05; #, p < 0.01. Tumor samples from each group were subject to immunoblotting analysis for PARP, Caspase-3, phospho-AKT, T-AKT, p-mTOR, T-mTOR, p-p70S6K, and p70S6K with specific antibodies (B, C, and D).